Unnamed: 0,title,date,stock,sentiment
854247.0,72 Biggest Movers From Friday,2020-06-01 04:53:00-04:00,MRNS,neutral
854248.0,50 Stocks Moving In Friday's Mid-Day Session,2020-05-29 12:15:00-04:00,MRNS,neutral
854249.0,Marinus Pharmaceuticals shares are trading lower after the company announced a proposed offering of common stock.,2020-05-29 08:18:00-04:00,MRNS,neutral
854250.0,20 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-05-29 07:39:00-04:00,MRNS,neutral
854251.0,"The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant",2020-05-29 07:22:00-04:00,MRNS,positive
854252.0,34 Stocks Moving in Friday's Pre-Market Session,2020-05-29 07:15:00-04:00,MRNS,neutral
854253.0,"6 Stocks To Watch For May 29, 2020",2020-05-29 04:57:00-04:00,MRNS,neutral
854254.0,10 Stocks Moving In Thursday's After-Hours Session,2020-05-28 17:58:00-04:00,MRNS,neutral
854255.0,Marinus Pharmaceuticals shares are trading lower after the company announced a proposed offering of common stock.,2020-05-28 16:13:00-04:00,MRNS,neutral
854256.0,Marinus Pharmaceuticals Announces A Proposed Offering Of The Company's Common Stock,2020-05-28 16:02:00-04:00,MRNS,neutral
854257.0,"Cantor Fitzgerald Reiterates Overweight on Marinus Pharmaceuticals, Lowers Price Target to $6",2020-05-05 06:44:00-04:00,MRNS,negative
854258.0,Marinus Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 EPS results.,2020-05-04 08:43:00-04:00,MRNS,neutral
854259.0,Marinus Pharmaceuticals Q1 EPS $(0.320) Misses $(0.160) Estimate,2020-05-04 07:33:00-04:00,MRNS,negative
854260.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,MRNS,neutral
854261.0,"Shares of several healthcare companies are trading lower, selling off from this week's strength. While the US stimulus package boosted economic optimism, demand concerns still exist amid the coronavirus outbreak.",2020-03-27 10:58:00-04:00,MRNS,positive
854262.0,"Marinus Pharmaceuticals Appoints Sasha Damouni Ellis As Vice President, Investor Relations And Corporate Communications",2020-03-19 07:31:00-04:00,MRNS,neutral
854263.0,18 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2020-03-17 08:58:00-04:00,MRNS,neutral
854264.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,MRNS,negative
854265.0,Dr. Anthony Fauci Says Covid-19 Vaccine Could be Ready for Testing in Two Months,2020-02-26 18:59:00-05:00,MRNS,positive
854266.0,Marinus Pharmaceuticals Completes Targeted Enrollment In Pivotal Phase 3 Study For CDKL5 Deficiency Disorder,2020-02-25 07:39:00-05:00,MRNS,negative
854267.0,Marinus Pharma Reports Completion Of Targeted Enrollment In Phase 3 Study For CDKL5 Deficiency Disorder,2020-02-25 07:37:00-05:00,MRNS,negative
854268.0,25 Stocks Moving in Monday's Pre-Market Session,2020-02-24 07:09:00-05:00,MRNS,neutral
854269.0,94 Biggest Movers From Friday,2020-02-24 04:53:00-05:00,MRNS,neutral
854270.0,68 Stocks Moving In Friday's Mid-Day Session,2020-02-21 12:29:00-05:00,MRNS,neutral
854271.0,33 Stocks Moving in Friday's Pre-Market Session,2020-02-21 07:15:00-05:00,MRNS,neutral
854272.0,95 Biggest Movers From Yesterday,2020-02-21 05:12:00-05:00,MRNS,neutral
854273.0,80 Biggest Movers From Yesterday,2020-02-19 04:28:00-05:00,MRNS,neutral
854274.0,43 Healthcare Stocks Moving In Tuesday's After-Market Session,2020-01-28 23:40:00-05:00,MRNS,neutral
854275.0,26 Biotechnology Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:28:00-05:00,MRNS,neutral
854276.0,36 Healthcare Stocks Moving In Wednesday's After-Market Session,2020-01-22 23:23:00-05:00,MRNS,neutral
854277.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,MRNS,neutral
854278.0,Marinus Says Enrollment On Track For CDKL5 Deficiency Disorder Phase 3 Readout In Q3 2020,2020-01-13 07:40:00-05:00,MRNS,negative
854279.0,"H.C. Wainwright Reiterates Buy on Marinus Pharmaceuticals, Raises Price Target to $6",2020-01-10 10:34:00-05:00,MRNS,neutral
854280.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-30 08:21:00-05:00,MRNS,neutral
854281.0,18 Stocks Moving in Thursday's Pre-Market Session,2019-12-26 07:35:00-05:00,MRNS,neutral
854282.0,20 Stocks Moving in Monday's Pre-Market Session,2019-12-23 07:44:00-05:00,MRNS,neutral
854283.0,60 Biggest Movers From Friday,2019-12-23 05:37:00-05:00,MRNS,neutral
854284.0,Mid-Afternoon Market Update: Dow Rises 125 Points; Care.com Shares Jump Following Acquisition News,2019-12-20 14:18:00-05:00,MRNS,positive
854285.0,Mid-Day Market Update: Crude Oil Down Over 1%; Stealth BioTherapeutics Shares Plummet,2019-12-20 12:15:00-05:00,MRNS,negative
854286.0,40 Stocks Moving In Friday's Mid-Day Session,2019-12-20 12:07:00-05:00,MRNS,neutral
854287.0,"Benzinga's Top Upgrades, Downgrades For December 20, 2019",2019-12-20 10:01:00-05:00,MRNS,positive
854288.0,Marinus Pharmaceuticals shares are trading higher after Oppenheimer initiated coverage on the stock with an Outperform rating and a price target of $6 per share.,2019-12-20 08:23:00-05:00,MRNS,positive
854289.0,28 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-12-20 08:19:00-05:00,MRNS,neutral
854290.0,"Oppenheimer Initiates Coverage On Marinus Pharmaceuticals with Outperform Rating, Announces $6 Price Target",2019-12-20 06:27:00-05:00,MRNS,neutral
854291.0,"Marinus Pharma Shares Indicated Up 9% After Hours As Hearing Oppenheimer Initiates Coverage On Stock With Outperform Rating, $6 Price Target",2019-12-19 16:21:00-05:00,MRNS,positive
854292.0,70 Biggest Movers From Yesterday,2019-12-12 06:31:00-05:00,MRNS,neutral
854293.0,Mid-Afternoon Market Update: Federal Reserve Maintains Interest Rates; United Natural Foods Shares Fall On Downbeat Earnings,2019-12-11 14:20:00-05:00,MRNS,positive
854294.0,50 Stocks Moving In Wednesday's Mid-Day Session,2019-12-11 12:11:00-05:00,MRNS,neutral
854295.0,Marinus Pharmaceuticals shares are trading higher despite pricing its common stock offering of 28 million shares at $1.25 per share.,2019-12-11 09:57:00-05:00,MRNS,positive
854296.0,Marinus Pharma Prices 28M Share Common Stock Offering At $1.25/Share,2019-12-11 09:07:00-05:00,MRNS,positive
854297.0,32 Stocks Moving In Wednesday's Pre-Market Session,2019-12-11 07:48:00-05:00,MRNS,neutral
854298.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,MRNS,negative
854299.0,Marinus Pharmaceuticals shares are trading lower after the company announced a common stock offering with no size disclosed.,2019-12-10 16:28:00-05:00,MRNS,negative
854300.0,"Marinus Pharmaceuticals Announces Common Stock Offering, No Size Disclosed; Announces Concurrent Private Placement",2019-12-10 16:27:00-05:00,MRNS,negative
854301.0,Marinus Pharma Gives Updates on its Orphan Epilepsy Program,2019-12-09 06:34:00-05:00,MRNS,neutral
854302.0,Marinus Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-12-05 11:45:00-05:00,MRNS,positive
854303.0,Marinus Shares Tick Higher On Volume As Traders Circulate EC Public Health Notice For Co.'s Ganaxolone,2019-11-18 13:06:00-05:00,MRNS,positive
854304.0,Marinus Pharmaceuticals Q3 EPS $(0.26) Up From $(0.27) YoY,2019-11-06 07:48:00-05:00,MRNS,neutral
854305.0,"Cantor Fitzgerald Assumes Marinus Pharmaceuticals at Overweight, Announces $7 Price Target",2019-10-18 10:30:00-04:00,MRNS,negative
854306.0,32 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-10-18 08:34:00-04:00,MRNS,neutral
854307.0,"The Daily Biotech Pulse: Akebia Sues CMS, Roche Raises Guidance Yet Again, Titan Medical Entangled In Credit Crunch",2019-10-16 07:06:00-04:00,MRNS,positive
854308.0,"The Week Ahead In Biotech: FDA Decisions, Johnson & Johnson Among Big Pharma Earnings",2019-10-13 16:33:00-04:00,MRNS,neutral
854309.0,Marinus Pharmaceuticals 13G Shows Venrock Healthcare Capital Partners Holds 7.6% Stake In Co.,2019-10-07 16:13:00-04:00,MRNS,neutral
854310.0,"The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear",2019-09-29 15:01:00-04:00,MRNS,positive
854311.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 27, 2019",2019-09-27 15:08:00-04:00,MRNS,neutral
854312.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Friday, September 27, 2019",2019-09-27 09:57:00-04:00,MRNS,positive
854313.0,21 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-27 08:45:00-04:00,MRNS,neutral
854314.0,50 Biggest Movers From Yesterday,2019-09-27 04:31:00-04:00,MRNS,neutral
854315.0,Mid-Afternoon Market Update: Crude Oil Down 1%; Marinus Pharmaceuticals Shares Spike Higher,2019-09-26 14:31:00-04:00,MRNS,negative
854316.0,"A Look At Benzinga Pro's Most-Searched Tickers For September 26, 2019",2019-09-26 13:30:00-04:00,MRNS,neutral
854317.0,34 Stocks Moving In Thursday's Mid-Day Session,2019-09-26 12:29:00-04:00,MRNS,neutral
854318.0,Mid-Day Market Update: Rite Aid Surges On Earnings Beat; BioXcel Therapeutics Shares Slide,2019-09-26 12:20:00-04:00,MRNS,positive
854319.0,Marinus Shares Rip Higher On Positive Ganaxolone Midstage Data In Epileptic Seizures,2019-09-26 11:16:00-04:00,MRNS,positive
854320.0,Mid-Morning Market Update: Markets Open Lower; Conagra Brands Earnings Beat Estimates,2019-09-26 10:18:00-04:00,MRNS,negative
854321.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Thursday, September 26, 2019",2019-09-26 09:35:00-04:00,MRNS,positive
854322.0,21 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-26 08:10:00-04:00,MRNS,neutral
854323.0,24 Stocks Moving in Thursday's Pre-Market Session,2019-09-26 07:44:00-04:00,MRNS,neutral
854324.0,Marinus Pharmaceuticals shares are trading higher after the company announced all patients in the Ganaxolone Phase 2 Refractory Status Epilepticus trial met the primary endpoint.,2019-09-26 07:40:00-04:00,MRNS,positive
854325.0,UPDATE: Marinus Says Is Planning for End-Of-Phase 2 Meeting With FDA,2019-09-26 07:31:00-04:00,MRNS,neutral
854326.0,Marinus Pharma Reports All Patients In Ganaxolone Phase 2 Refractory Status Epilepticus Trial Met Primary Endpoint,2019-09-26 07:30:00-04:00,MRNS,neutral
854327.0,Marinus Pharmaceuticals shares are trading lower on seemingly no company-specific news.,2019-09-18 14:24:00-04:00,MRNS,negative
854328.0,"Benzinga's Top Upgrades, Downgrades For September 3, 2019",2019-09-03 09:42:00-04:00,MRNS,positive
854329.0,"H.C. Wainwright Initiates Coverage On Marinus Pharmaceuticals with Buy Rating, Announces $5 Price Target",2019-09-03 08:19:00-04:00,MRNS,neutral
854330.0,Marinus Pharmaceuticals shares are trading higher after the company reported Q2 results.,2019-08-08 12:46:00-04:00,MRNS,positive
854331.0,"Marinus Pharmaceuticals Earlier Reported Q2 EPS $(0.24), Inline; Top-Line Phase 2 Refractory Status Epilepticus (Rse) Data On-Track For Q3 2019; Scott Braunstein Appointed As CEO; Nicole Vitullo Appointed As Chairman Of The Board",2019-08-08 10:50:00-04:00,MRNS,neutral
854332.0,28 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-02 09:07:00-04:00,MRNS,neutral
854333.0,45 Healthcare Stocks Moving In Monday's After-Market Session,2019-07-30 04:54:00-04:00,MRNS,neutral
854334.0,40 Healthcare Stocks Moving In Friday's After-Market Session,2019-07-29 04:25:00-04:00,MRNS,neutral
854335.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,MRNS,negative
854336.0,30 Healthcare Stocks Moving In Thursday's After-Market Session,2019-07-26 04:36:00-04:00,MRNS,neutral
854337.0,"Top 10 Most Oversold Stocks Via Benzinga Pro's Screener Tool For Thu., July 25, 2019",2019-07-25 13:42:00-04:00,MRNS,positive
854338.0,"The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug",2019-07-25 07:21:00-04:00,MRNS,negative
854339.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,MRNS,neutral
854340.0,"A Look At Benzinga Pro's Most-Searched Tickers For July 24, 2019",2019-07-24 12:30:00-04:00,MRNS,neutral
854341.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Wednesday., July 24, 2019",2019-07-24 11:36:00-04:00,MRNS,positive
854342.0,"The Daily Biotech Pulse: Jounce Jumps On Licensing Deal, Regulus Hit With Partial Clinical Hold, Genomic Health Added to S&P SmallCap Index",2019-07-24 07:08:00-04:00,MRNS,neutral
854343.0,60 Biggest Movers From Yesterday,2019-07-24 04:57:00-04:00,MRNS,neutral
854344.0,List of Companies Reaching Yearly Lows Tuesday,2019-07-23 14:58:00-04:00,MRNS,neutral
854345.0,Mid-Afternoon Market Update: Dow Rises Over 150 Points; LSC Communications Shares Plunge,2019-07-23 14:36:00-04:00,MRNS,positive
854346.0,Marinus Pharmaceuticals shares are trading lower after the company reported disappointing Phase 2 trial results for its IV Ganaxolone.,2019-07-23 13:23:00-04:00,MRNS,negative
854347.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-07-23 13:09:00-04:00,MRNS,neutral
854348.0,Mid-Day Market Update: Tile Shop Falls After Q2 Results; Chiasma Shares Surge,2019-07-23 12:42:00-04:00,MRNS,positive
854349.0,Marinus Sinks To 2-Year Low As Postpartum Depression Drug Found Ineffective At 28 Days,2019-07-23 11:30:00-04:00,MRNS,negative
854350.0,Mid-Morning Market Update: Markets Open Higher; Coca-Cola Tops Q2 Estimates,2019-07-23 10:54:00-04:00,MRNS,positive
854351.0,"Marinus Pharma Shares Resume Trade, Down 64%",2019-07-23 08:02:00-04:00,MRNS,positive
854352.0,"Marinus Pharma Reports IV Ganaxolone Results From Phase 2 Of Phase 2 Magnolia Trial Showed Was Generally Safe, Well-Tolerated, Provided Clinically Meaningful Reductions In Hamilton Rating Scale For Depression",2019-07-23 07:43:00-04:00,MRNS,positive
854353.0,"Marinus Pharmaceuticals Shares Halted, News Pending",2019-07-23 07:30:00-04:00,MRNS,positive
854354.0,54 Biggest Movers From Yesterday,2019-06-14 05:02:00-04:00,MRNS,neutral
854355.0,Marinus Pharma Shares Dip Sharply Below $4.80 Level; Stock Now Down 4% For Session,2019-05-16 12:49:00-04:00,MRNS,positive
854356.0,Marinus Pharmaceuticals Receives Worldwide Patent For Treatment Of Epileptic Disorders From The CDKL5 Genetic Mutation,2019-05-16 11:12:00-04:00,MRNS,neutral
854357.0,78 Biggest Movers From Yesterday,2019-05-03 05:08:00-04:00,MRNS,neutral
854358.0,60 Biggest Movers From Yesterday,2019-05-02 06:10:00-04:00,MRNS,neutral
854359.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-05-01 13:24:00-04:00,MRNS,neutral
854360.0,Marinus Pharmaceuticals Q1 EPS $(0.24) Misses $(0.21) Estimate,2019-05-01 07:45:00-04:00,MRNS,negative
854361.0,Marinus Pharmaceuticals Initiates Phase 3 Study In Children With PCDH19-Related Epilepsy,2019-03-06 07:43:00-05:00,MRNS,neutral
854362.0,Jefferies Sees Opportunity In Marinus Pharmaceuticals: 4 Reasons Why,2019-03-05 14:51:00-05:00,MRNS,positive
854363.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2019",2019-03-05 09:12:00-05:00,MRNS,positive
854364.0,"Jefferies Initiates Coverage On Marinus Pharmaceuticals with Buy Rating, Announces $10 Price Target",2019-03-05 08:12:00-05:00,MRNS,neutral
854365.0,10 Biggest Price Target Changes For Wednesday,2019-02-27 10:22:00-05:00,MRNS,neutral
854366.0,"Mizuho Downgrades Marinus Pharmaceuticals to Neutral, Lowers Price Target to $5",2019-02-27 07:08:00-05:00,MRNS,negative
854367.0,"Marinus Pharma Reports CEO Christopher ""Cashman To Leave Co.; Scott Braunstein Named Executive Chair; Co. Has Retained Exec Search Firm To Identify Successor",2019-02-26 09:13:00-05:00,MRNS,positive
854368.0,"Marinus Pharma Shares Spike Higher Amid Circulation Of ClinicalTrials.gov Notice Showing Recruitment Completed, Results First Posted Feb. 18, 2019 For Its Augmentation of Treatment-Resistant Depression With Analog of Neuroactive Steroid Allopregnanolone",2019-02-25 13:09:00-05:00,MRNS,negative
854369.0,71 Biggest Movers From Friday,2019-02-25 05:04:00-05:00,MRNS,neutral
854370.0,"Benzinga's Top Upgrades, Downgrades For February 6, 2019",2019-02-06 09:14:00-05:00,MRNS,positive
854371.0,33 Stocks Moving In Wednesday's Pre-Market Session,2019-02-06 08:27:00-05:00,MRNS,neutral
854372.0,"Leerink Swann Initiates Coverage On Marinus Pharmaceuticals with Outperform Rating, Announces $10 Price Target",2019-02-06 07:54:00-05:00,MRNS,neutral
854373.0,60 Biggest Movers From Friday,2019-02-04 05:05:00-05:00,MRNS,neutral
854374.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2018-12-30 15:27:00-05:00,MRNS,neutral
854375.0,55 Biggest Movers From Monday,2018-12-26 04:38:00-05:00,MRNS,neutral
854376.0,40 Stocks Moving In Monday's Mid-Day Session,2018-12-24 12:15:00-05:00,MRNS,neutral
854377.0,60 Biggest Movers From Friday,2018-12-24 04:35:00-05:00,MRNS,neutral
854378.0,The Week Ahead In Biotech: Focus Shifts To Year-End Clinical Trial Results,2018-12-23 10:37:00-05:00,MRNS,neutral
854379.0,"The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum",2018-12-20 07:53:00-05:00,MRNS,positive
854380.0,"Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018",2018-12-19 12:43:00-05:00,MRNS,negative
854381.0,Marinus Pharmaceuticals Entered Into Underwriting Agreement To Offer 12M Shares @$3.75/Skare,2018-12-16 07:43:00-05:00,MRNS,positive
854382.0,51 Biggest Movers From Yesterday,2018-12-14 05:00:00-05:00,MRNS,neutral
854383.0,36 Stocks Moving In Thursday's Mid-Day Session,2018-12-13 13:11:00-05:00,MRNS,neutral
854384.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-12-13 08:02:00-05:00,MRNS,neutral
854385.0,"The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen",2018-12-13 07:56:00-05:00,MRNS,positive
854386.0,52 Biggest Movers From Yesterday,2018-12-13 04:54:00-05:00,MRNS,neutral
854387.0,Marinus Pharmaceuticals Announces Prices 12M Share Public Offering of Common Stock @$3.75/Share,2018-12-13 04:24:00-05:00,MRNS,positive
854388.0,Mid-Afternoon Market Update: Sparton Climbs On Acquisition News; Synergy Pharmaceuticals Shares Slide,2018-12-12 14:39:00-05:00,MRNS,positive
854389.0,41 Stocks Moving In Wednesday's Mid-Day Session,2018-12-12 12:33:00-05:00,MRNS,neutral
854390.0,Mid-Day Market Update: NASDAQ Rises 2%; Neurocrine Biosciences Shares Plunge,2018-12-12 12:04:00-05:00,MRNS,positive
854391.0,Mid-Morning Market Update: Markets Open Higher; Vera Bradley Misses Q3 Estimates,2018-12-12 10:18:00-05:00,MRNS,negative
854392.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,MRNS,positive
854393.0,31 Stocks Moving In Wednesday's Pre-Market Session,2018-12-12 08:04:00-05:00,MRNS,neutral
854394.0,A Peek Into The Markets: US Stock Futures Higher Ahead Of Consumer Price Index,2018-12-12 07:15:00-05:00,MRNS,neutral
854395.0,"8 Stocks To Watch For December 12, 2018",2018-12-12 04:58:00-05:00,MRNS,neutral
854396.0,Marinus Pharmaceuticals are down after hours following the company's announcement of a 12 million share common stock offering.,2018-12-11 16:42:00-05:00,MRNS,positive
854397.0,Marinus Pharma Reports Offering Of 12M Shares Of Common Stock,2018-12-11 16:02:00-05:00,MRNS,positive
854398.0,Marinus Pharma's Postpartum Depression Candidate Aces Midstage Trials,2018-12-10 12:50:00-05:00,MRNS,negative
854399.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Afternoon Of Mon., Dec. 10, 2018",2018-12-10 12:22:00-05:00,MRNS,positive
854400.0,Marinus Pharma Shares Rebound From Under $5 Level Over Last Few Mins.; Traders Circulating Word Of New Street-High Price Target Of $29 At JMP,2018-12-10 11:37:00-05:00,MRNS,positive
854401.0,"Baird Out Defending Marinus Pharmaceuticals, Says IV Ganaxolone Data Results Appear To Indicate An Active GABAergic Drug",2018-12-10 10:24:00-05:00,MRNS,positive
854402.0,31 Stocks Moving In Monday's Pre-Market Session,2018-12-10 08:16:00-05:00,MRNS,neutral
854403.0,Marinus Pharmaceuticals shares are trading higher after the company announced positive Ganaxolone data in women with postpartum depression.,2018-12-10 07:54:00-05:00,MRNS,positive
854404.0,Marinus Pharmaceuticals Announces 'Positive' Ganaxolone Data in Women With Postpartum Depression,2018-12-10 07:36:00-05:00,MRNS,negative
854405.0,60 Biggest Movers From Yesterday,2018-12-07 04:42:00-05:00,MRNS,neutral
854406.0,Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients,2018-12-04 07:38:00-05:00,MRNS,negative
854407.0,42 Stocks Moving In Monday's Mid-Day Session,2018-10-29 12:21:00-04:00,MRNS,neutral
854408.0,Marinus Pharmaceuticals Q3 EPS $(0.27) Misses $(0.21) Estimate,2018-10-29 07:31:00-04:00,MRNS,negative
854409.0,41 Biggest Movers From Yesterday,2018-10-11 05:22:00-04:00,MRNS,neutral
854410.0,"Stocks Which Set New 52-Week High Yesterday, October 1st",2018-10-02 09:20:00-04:00,MRNS,neutral
854411.0,48 Biggest Movers From Yesterday,2018-10-02 04:51:00-04:00,MRNS,neutral
854412.0,Marinus Completes Enrollment In Its Magnolia Postpartum Depression Study,2018-09-25 07:31:00-04:00,MRNS,negative
854413.0,75 Biggest Movers From Yesterday,2018-08-03 06:10:00-04:00,MRNS,neutral
854414.0,65 Stocks Moving In Thursday's Mid-Day Session,2018-08-02 12:26:00-04:00,MRNS,neutral
854415.0,Marinus Pharmaceuticals shares are trading 16% lower after reporting weak quarterly financial results. The company also delayed the readout for its ganaxalone study by a quarter for the second time this year.,2018-08-02 09:50:00-04:00,MRNS,negative
854416.0,"'$MRNS has delayed the readout of its ganaxalone postpartum depression study again, this time to the fourth quarter. (Was supposed to happen this quarter, and before that, the first quarter.)'-STAT's Adam Feurestein Tweets",2018-08-02 07:52:00-04:00,MRNS,negative
854417.0,Marinus Pharmaceuticals Q2 EPS $(0.24) Misses $(0.16) Estimate,2018-08-02 07:33:00-04:00,MRNS,negative
854418.0,Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus,2018-07-21 08:44:00-04:00,MRNS,neutral
854419.0,44 Biggest Movers From Yesterday,2018-07-03 05:54:00-04:00,MRNS,neutral
854420.0,38 Stocks Moving In Monday's Mid-Day Session,2018-07-02 12:29:00-04:00,MRNS,neutral
854421.0,"Benzinga's Top Upgrades, Downgrades For July 2, 2018",2018-07-02 09:21:00-04:00,MRNS,positive
854422.0,"Cantor Fitzgerald Initiates Coverage On Marinus Pharmaceuticals with Overweight Rating, Announces $19 Price Target",2018-07-02 09:13:00-04:00,MRNS,negative
854423.0,Marinus Pharma Reports Initiation Of Pivotal Phase 3 Trial In Children' With CDKL5 Deficiency Disorder,2018-06-19 07:32:00-04:00,MRNS,negative
854424.0,40 Biggest Movers From Yesterday,2018-06-07 04:50:00-04:00,MRNS,neutral
854425.0,"Marinus Pharmaceuticals Has 3 Major Catalysts In 2018, Ladenburg Thalmann Says In Bullish Initiation",2018-06-06 15:43:00-04:00,MRNS,neutral
854426.0,28 Stocks Moving In Wednesday's Mid-Day Session,2018-06-06 12:24:00-04:00,MRNS,neutral
854427.0,"Benzinga's Top Upgrades, Downgrades For June 6, 2018",2018-06-06 09:16:00-04:00,MRNS,positive
854428.0,"Ladenburg Thalmann Initiates Coverage On Marinus Pharmaceuticals with Buy Rating, Announces $20 Price Target",2018-06-06 07:39:00-04:00,MRNS,neutral
854429.0,45 Biggest Movers From Yesterday,2018-05-25 04:37:00-04:00,MRNS,neutral
854430.0,42 Stocks Moving In Thursday's Mid-Day Session,2018-05-24 13:31:00-04:00,MRNS,neutral
854431.0,"Benzinga's Top Upgrades, Downgrades For May 24, 2018",2018-05-24 09:40:00-04:00,MRNS,positive
854432.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-05-24 08:40:00-04:00,MRNS,neutral
854433.0,"Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings",2018-05-24 08:37:00-04:00,MRNS,neutral
854434.0,"Baird Initiates Coverage On Marinus Pharmaceuticals with Outperform Rating, Announces $15 Price Target",2018-05-24 08:33:00-04:00,MRNS,neutral
854435.0,9 Stocks Moving In Wednesday's After-Hours Session,2018-05-23 17:13:00-04:00,MRNS,neutral
854436.0,"Marinus Shares Up 6.1% After Baird Initiated Coverage With Outperform Rating, $15 Price Target",2018-05-23 16:46:00-04:00,MRNS,positive
854437.0,"Marinus Pharma Shares Indicated Up 7.3% After Hours As Baird Initiates Coverage With Outperform Rating, $15 Price Target",2018-05-23 16:16:00-04:00,MRNS,positive
854438.0,55 Biggest Movers From Yesterday,2018-05-03 04:42:00-04:00,MRNS,neutral
854439.0,43 Stocks Moving In Wednesday's Mid-Day Session,2018-05-02 13:30:00-04:00,MRNS,neutral
854440.0,Marinus Pharmaceuticals Q1 EPS $(0.15) Beats $(0.16) Estimate,2018-05-02 08:25:00-04:00,MRNS,neutral
854441.0,18 Stocks Moving In Wednesday's Pre-Market Session,2018-04-04 08:19:00-04:00,MRNS,neutral
854442.0,Mid-Afternoon Market Update: MuleSoft Gains Following Report Of Takeover Interest From Salesforce; Proteostasis Therapeutics Shares Slide,2018-03-20 14:34:00-04:00,MRNS,positive
854443.0,28 Stocks Moving In Tuesday's Mid-Day Session,2018-03-20 13:46:00-04:00,MRNS,neutral
854444.0,Mid-Day Market Update: Crude Oil Up 2.5%; Arena Pharmaceuticals Shares Spike Higher,2018-03-20 12:35:00-04:00,MRNS,negative
854445.0,Mid-Morning Market Update: Markets Gain; Oracle Shares Fall Following Q3 Results,2018-03-20 10:35:00-04:00,MRNS,positive
854446.0,"Benzinga's Top Upgrades, Downgrades For March 20, 2018",2018-03-20 10:10:00-04:00,MRNS,positive
854447.0,"Mizuho Initiates Coverage On Marinus Pharmaceuticals with Buy Rating, Announces $13.00 Price Target",2018-03-20 07:34:00-04:00,MRNS,neutral
854448.0,41 Biggest Movers From Yesterday,2018-03-08 04:46:00-05:00,MRNS,neutral
854449.0,"Adam Feuerstein Tweets: Marinus Pharma $MRNS finds the biotech imitation game can only last so long, ""We're just like $SAGE "" wearing thin.",2018-03-07 07:09:00-05:00,MRNS,positive
854450.0,44 Biggest Movers From Yesterday,2018-03-07 05:03:00-05:00,MRNS,neutral
854451.0,Mid-Afternoon Market Update: Freshpet Slides On Earnings Miss; CommerceHub Shares Surge,2018-03-06 14:30:00-05:00,MRNS,positive
854452.0,Marinus Pharamaceuticals Shares Down 14.7% Following FY17 Earnings Miss,2018-03-06 12:52:00-05:00,MRNS,positive
854453.0,38 Stocks Moving In Tuesday's Mid-Day Session,2018-03-06 12:27:00-05:00,MRNS,neutral
854454.0,Mid-Day Market Update: Dow Falls Over 100 Points; Amedica Shares Spike Higher,2018-03-06 12:02:00-05:00,MRNS,positive
854455.0,"Marinus Pharma Reports FY 2017 EPS $(0.80) vs $(0.71) Est., No Sales",2018-03-06 07:35:00-05:00,MRNS,negative
854456.0,32 Biggest Movers From Yesterday,2018-03-06 05:08:00-05:00,MRNS,neutral
854457.0,42 Biggest Movers From Friday,2018-03-05 05:08:00-05:00,MRNS,neutral
854458.0,Marinus Pharma Option Alert: Mar 16 $7.5 Calls at the Bid: 7200 @ $1.25 vs 4858 OI; Earnings 3/12 Before Open [est] Ref=$6.43,2018-02-15 11:55:00-05:00,MRNS,positive
854459.0,19 Biotech Stocks With Clinical Trial Outcomes In February,2018-02-08 16:41:00-05:00,MRNS,neutral
854460.0,"STAT News' Adam Feuerstein Tweets '$MRNS is the third-best performing biotech stock this year on the ""next $SAGE thesis"" â€” and it could (probably?) all come crashing down in 2018 when PPD/SSRE data read out.'",2017-12-22 14:29:00-05:00,MRNS,neutral
854461.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,MRNS,neutral
854462.0,40 Biggest Movers From Yesterday,2017-12-19 05:15:00-05:00,MRNS,neutral
854463.0,33 Biggest Movers From Friday,2017-12-18 05:45:00-05:00,MRNS,neutral
854464.0,32 Biggest Movers From Yesterday,2017-12-15 05:43:00-05:00,MRNS,neutral
854465.0,32 Stocks Moving In Thursday's Mid-Day Session,2017-12-14 12:44:00-05:00,MRNS,neutral
854466.0,36 Biggest Movers From Friday,2017-12-11 06:02:00-05:00,MRNS,neutral
854467.0,25 Stocks Moving In Friday's Mid-Day Session,2017-12-08 12:01:00-05:00,MRNS,neutral
854468.0,Why Marinus Pharmaceuticals Shares Spiked On Sage Therapeutics News,2017-12-08 08:34:00-05:00,MRNS,positive
854469.0,23 Stocks Moving In Friday's Pre-Market Session,2017-12-08 08:12:00-05:00,MRNS,neutral
854470.0,32 Biggest Movers From Yesterday,2017-12-08 05:05:00-05:00,MRNS,neutral
854471.0,31 Stocks Moving In Thursday's Mid-Day Session,2017-12-07 12:24:00-05:00,MRNS,neutral
854472.0,"Marinus Pharmaceuticals Shares Up 16.64% On 2x Avg. Volume, Perhaps In Sympathy With Sage Therapeutics After It's Positive Phase 2 Results; Both Develop Neuropsychiatric Disorder Treatments",2017-12-07 10:39:00-05:00,MRNS,positive
854473.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-12-07 08:02:00-05:00,MRNS,neutral
854474.0,51 Biggest Movers From Yesterday,2017-11-10 05:30:00-05:00,MRNS,neutral
854475.0,40 Stocks Moving In Thursday's Mid-Day Session,2017-11-09 12:32:00-05:00,MRNS,neutral
854476.0,30 Stocks Moving In Thursday's Pre-Market Session,2017-11-09 08:14:00-05:00,MRNS,neutral
854477.0,Marinus Pharma S-3 Filing Shows Registration For $200M Mixed Securities Shelf Offering,2017-10-31 16:39:00-04:00,MRNS,positive
854478.0,Marinus Pharma Reports Q3 EPS $(0.15) vs $(0.17) Est.,2017-10-31 07:44:00-04:00,MRNS,neutral
854479.0,32 Stocks Moving In Wednesday's Mid-Day Session,2017-10-18 12:53:00-04:00,MRNS,neutral
854480.0,12 Biggest Mid-Day Gainers For Tuesday,2017-10-10 12:22:00-04:00,MRNS,neutral
854481.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,MRNS,neutral
854482.0,18 Biggest Mid-Day Losers For Monday,2017-10-09 12:55:00-04:00,MRNS,negative
854483.0,"Adam Feuerstein Tweets: Trying again:

Best performers in Q3: $DMTX $MRNS $MYOK

Worst: $OTIC $AXON $ICPT",2017-09-29 16:24:00-04:00,MRNS,neutral
854484.0,20 Biggest Mid-Day Gainers For Monday,2017-09-25 12:43:00-04:00,MRNS,neutral
854485.0,18 Biggest Mid-Day Gainers For Friday,2017-09-15 12:21:00-04:00,MRNS,neutral
854486.0,Marinus Pharma Prices 9.33M Share Offering at $3.75/Share,2017-09-15 07:30:00-04:00,MRNS,positive
854487.0,A Peek Into The Markets: U.S. Stock Futures Edge Lower Ahead Of Economic Reports,2017-09-15 07:06:00-04:00,MRNS,negative
854488.0,"5 Stocks To Watch For September 15, 2017",2017-09-15 04:47:00-04:00,MRNS,neutral
854489.0,"Marinus Pharmaceuticals Announces Offering Common Stock, No Size Disclosed",2017-09-14 16:01:00-04:00,MRNS,negative
854490.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-09-13 08:04:00-04:00,MRNS,neutral
854491.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-09-12 08:04:00-04:00,MRNS,neutral
854492.0,Mid-Afternoon Market Update: Crude Oil Up Over 1%; Alamos Gold Shares Slide,2017-09-11 14:31:00-04:00,MRNS,negative
854493.0,20 Biggest Mid-Day Gainers For Monday,2017-09-11 12:29:00-04:00,MRNS,neutral
854494.0,Mid-Day Market Update: Dow Up 1%; Achillion Pharmaceuticals Shares Plunge,2017-09-11 12:05:00-04:00,MRNS,positive
854495.0,Mid-Morning Market Update: Markets Open Higher; Teva Pharmaceutical Names Kaare Schultz As CEO,2017-09-11 10:09:00-04:00,MRNS,neutral
854496.0,18 Stocks Moving In Monday's Pre-Market Session,2017-09-11 08:27:00-04:00,MRNS,neutral
854497.0,Marinus Gives Trial Results from its Phase 2 Study of CDKL5,2017-09-11 07:38:00-04:00,MRNS,neutral
854498.0,15 Biggest Mid-Day Gainers For Monday,2017-08-14 12:42:00-04:00,MRNS,neutral
854499.0,EcoR1 Capital Reports 12.2% Stake In Marinus Pharmaceuticals,2017-08-08 13:35:00-04:00,MRNS,neutral
854500.0,Marinus Pharmaceuticals Reports Q2 EPS $(0.21) vs $(0.27) Est.,2017-08-01 07:32:00-04:00,MRNS,neutral
854501.0,13G Filing Shows Granite Point Capital Reporting 4.74% Stake In Marinus Pharmaceuticals,2017-07-18 16:09:00-04:00,MRNS,neutral
854502.0,"13G Filing Shows Deerfield Management, James Flynn Reporting 9.98% Stake In Marinua Pharmaceuticals,",2017-07-17 17:20:00-04:00,MRNS,neutral
854503.0,Marinus Pharmaceuticals Reports FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder,2017-06-29 14:29:00-04:00,MRNS,negative
854504.0,Marinus Pharmaceuticals Launches Ganaxolone Clinical Program in Patients with Postpartum Depression,2017-06-27 07:31:00-04:00,MRNS,negative
854505.0,"Marinus Pharma Reports Q1 EPS $(0.26) vs $(0.30) Est., $(0.37) in Same Qtr. Last Year",2017-05-01 07:36:00-04:00,MRNS,neutral
854506.0,"8-K from Marinus Pharma Shows Co. Entered License Deal, Supply Deal with CyDex Pharma for Exclusive Use of Captisol System, Related IP, No Specific Terms Disclosed",2017-04-06 16:38:00-04:00,MRNS,negative
854507.0,"Ligand Enters Commercial License, Supply Agreements with Marinus Pharmaceuticals for Captisol-Enabled Ganaxolone",2017-04-05 09:01:00-04:00,MRNS,positive
854508.0,Marinus Pharmaceuticals Reports FY16 EPS $(1.47) vs. $(1.48) Est.,2017-03-13 07:31:00-04:00,MRNS,neutral
854509.0,Mid-Afternoon Market Update: Crude Oil Down Over 1%; Brookfield Canada Office Properties Shares Spike Higher,2017-01-23 14:48:00-05:00,MRNS,negative
854510.0,15 Biggest Mid-Day Gainers For Monday,2017-01-23 12:30:00-05:00,MRNS,neutral
854511.0,Mid-Day Market Update: Marinus Pharma Surges Following Preliminary Study Update; QUALCOMM Shares Slide,2017-01-23 12:15:00-05:00,MRNS,positive
854512.0,Mid-Morning Market Update: Markets Open Slightly Lower; McDonald's Beats Q4 Estimates,2017-01-23 09:57:00-05:00,MRNS,negative
854513.0,20 Stocks Moving In Monday's Pre-Market Session,2017-01-23 08:19:00-05:00,MRNS,neutral
854514.0,Marinus Pharma Shares up 38% on Light Volume Following Preliminary Study Update,2017-01-23 07:34:00-05:00,MRNS,positive
854515.0,Marinus Announces 'Positive' Preliminary Data From Children With CDKL5 Genetic Disorder,2017-01-23 07:32:00-05:00,MRNS,negative
854516.0,Marinus Pharma Spikes to High of $1.41 on Volume,2017-01-17 14:08:00-05:00,MRNS,neutral
854517.0,12 Biggest Mid-Day Losers For Friday,2017-01-13 12:44:00-05:00,MRNS,negative
854518.0,"Marinus Lists 2017 Catalysts, Plans to Initiate Phase 2 Trial in Women with PPD in 1H 2017",2017-01-05 07:31:00-05:00,MRNS,neutral
854519.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-01-03 08:11:00-05:00,MRNS,neutral
854520.0,Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone,2017-01-03 07:30:00-05:00,MRNS,neutral
854521.0,"Must Watch Stocks for January 3, 2017",2017-01-03 06:16:00-05:00,MRNS,neutral
854522.0,10 Biggest Mid-Day Gainers For Friday,2016-12-30 12:31:00-05:00,MRNS,neutral
854523.0,Mid-Day Market Update: Opko Health Drops After Disappointing Phase 3 Study of hGH-CTP; Cempra Shares Surge,2016-12-30 12:19:00-05:00,MRNS,negative
854524.0,Mid-Morning Market Update: Markets Edge Lower; Golden Meditech Agrees To Sell Interest In China Cord Blood,2016-12-30 09:54:00-05:00,MRNS,positive
854525.0,18 Stocks Moving In Friday's Pre-Market Session,2016-12-30 08:16:00-05:00,MRNS,neutral
854526.0,Marinus Pharmaceuitcal Shares Up 32.9% As ganaxolone Receives Orphan Drug Designation For Treatment Of Fragile X Syndrome,2016-12-30 08:12:00-05:00,MRNS,positive
854527.0,Stocks Hitting 52-Week Lows,2016-12-14 10:54:00-05:00,MRNS,negative
854528.0,Marinus Pharmaceuticals Data P Resented On Ganaxolone and Diazepam Administered Intravenously Synergistically Block Seizures in Animal Model of Status Epilepticus,2016-11-15 07:40:00-05:00,MRNS,negative
854529.0,Marinus Pharmaceuticals Reports Q3 EPS $(0.33) vs. Est. $(0.43),2016-11-03 07:35:00-04:00,MRNS,neutral
854530.0,Ganaxolone Phase 1 Data Supports Progressing to Phase 2 in Patients with Status Epilepticus,2016-10-19 07:30:00-04:00,MRNS,positive
854531.0,12 Biggest Mid-Day Losers For Thursday,2016-09-29 13:10:00-04:00,MRNS,negative
854532.0,"Shares of Of Marinus Pharmaceuticals Down 27% On Earlier Data, Traders Attributing Weakness To Small Population Size And 5 Patients Who Discontinued Study Due To Efficacy or Adverse Event",2016-09-29 11:52:00-04:00,MRNS,negative
854533.0,"Bio Pharma Companies Expected To Report Data By Friday Sept. 30 Include Genocea Biosciences, SCYNEXIS, Threshold Pharmaceuticals, Arbutus Biopharma, Cytori Therapeutics, Esperion Therapeutics, Mesoblast, Marinus Pharmaceuticals, & Syndax Pharmaceuticals",2016-09-26 17:17:00-04:00,MRNS,neutral
854534.0,Marinus Pharma Reports Q2 Loss/Share  ($0.46) vs Est Loss/Share ($0.38),2016-08-09 16:49:00-04:00,MRNS,neutral
854535.0,Marinus Pharmaceuticals Spikes to High of $2.14 on Vol,2016-07-15 15:15:00-04:00,MRNS,neutral
854536.0,Sphera Global Healthcare Management Reports 6% Passive Stake In Marinus Pharmaceuticals in 13G,2016-07-06 09:43:00-04:00,MRNS,positive
854537.0,Marinus Pharma Phase 2 Ganaxolone Study Does Not Meet Primary Endpoint,2016-06-28 07:32:00-04:00,MRNS,neutral
854538.0,"Marinus Pharmaceuticals Doses Initial Subject in Phase 1 Clinical Trial for Ganaxolone IV, Ganaxolone IV Program Aimed at Status Epilepticus Target Indication",2016-06-22 07:31:00-04:00,MRNS,neutral
854539.0,"Oppenheimer Downgrades Marinus Pharmaceuticals, Removes Price Target On Disappointing Epilepsy Study Results",2016-06-14 15:41:00-04:00,MRNS,negative
854540.0,Benzinga's Top Downgrades,2016-06-14 08:53:00-04:00,MRNS,positive
854541.0,12 Stocks Moving In Tuesday's Pre-Market Session,2016-06-14 08:19:00-04:00,MRNS,neutral
854542.0,Oppenheimer Downgrades Marinus Pharmaceuticals to Perform,2016-06-14 07:27:00-04:00,MRNS,neutral
854543.0,RBC Capital Downgrades Marinus Pharmaceuticals to Sector Perform,2016-06-14 07:17:00-04:00,MRNS,neutral
854544.0,Mid-Afternoon Market Update: Dow Falls 75 Points; Eleven Biotherapeutics Shares Spike Higher,2016-06-13 14:30:00-04:00,MRNS,positive
854545.0,7 Biggest Mid-Day Losers For Monday,2016-06-13 13:20:00-04:00,MRNS,negative
854546.0,Mid-Day Market Update: Smith & Wesson Rises Following Orlando Shootings on Sunday; BioScrip Shares Slide,2016-06-13 12:07:00-04:00,MRNS,positive
854547.0,Stocks Hitting 52-Week Lows,2016-06-13 10:23:00-04:00,MRNS,negative
854548.0,Mid-Morning Market Update: Markets Edge Lower; Microsoft To Acquire LinkedIn For $26 Billion,2016-06-13 09:58:00-04:00,MRNS,negative
854549.0,Marinus Pharma Shares to Resume Trade at 8 a.m. EDT,2016-06-13 07:58:00-04:00,MRNS,positive
854550.0,UPDATE: Marinus Pharmaceuticals Says 25% Of Patients That Discontinued The Study Was Due To Adverse Events,2016-06-13 07:32:00-04:00,MRNS,negative
854551.0,"Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures, Did Not Meet Primary Endpoint",2016-06-13 07:31:00-04:00,MRNS,neutral
854552.0,Marinus Pharmaceuticals Inc Halted News Pending,2016-06-13 07:29:00-04:00,MRNS,neutral
854553.0,"Chardan Expecting Nearly 50% Downside In Sage Therapeutics, Starts At Sell",2016-05-24 07:03:00-04:00,MRNS,negative
854554.0,Marinus Pharma Reports Q1 EPS $(0.37) vs $(0.50) in Same Qtr. Last Year,2016-05-02 07:31:00-04:00,MRNS,neutral
854555.0,UPDATE: Marinus Pharmaceuticals Phase 1 Clinical Program On-Track To Initiate 1st Half 2016,2016-04-19 07:35:00-04:00,MRNS,neutral
854556.0,Marinus Pharma Says Ganaxolone IV Shows Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus,2016-04-19 07:34:00-04:00,MRNS,positive
854557.0,Marinus Pharmaceuticals Gets FDA Orphan Drug Status For Ganaxolone IV,2016-04-15 10:04:00-04:00,MRNS,neutral
854558.0,Marinus Pharmaceuticals Gets FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus,2016-04-15 07:31:00-04:00,MRNS,positive
854559.0,Marinus Pharmaceuticals Inc Reports Q4 EPS $(0.45) Vs Est $(0.36),2016-03-07 07:33:00-05:00,MRNS,neutral
854560.0,"CORRECTION: RBC Capital Initiates Coverage on Marinus Pharmaceuticals at Outperform, Announces $14.00 PT",2015-12-17 10:46:00-05:00,MRNS,neutral
854561.0,"RBC Capital Initiates Coverage on Marinus Pharmaceuticals at Outperform, Announces $14.00 PT",2015-12-17 10:45:00-05:00,MRNS,neutral
854562.0,Marinus Shows Additional Responder Analysis Data for Ganaxolone in Onset Seizures at the American Epilepsy Society Annual Meeting,2015-12-07 09:11:00-05:00,MRNS,neutral
854563.0,Stocks Hitting 52-Week Lows,2015-11-06 10:17:00-05:00,MRNS,negative
854564.0,Morning Market Losers,2015-11-06 09:53:00-05:00,MRNS,negative
854565.0,Marinus Pharmaceuticals Prices 5M Shares At $6/Share,2015-11-06 09:14:00-05:00,MRNS,positive
854566.0,Benzinga's Top #PreMarket Losers,2015-11-06 08:19:00-05:00,MRNS,negative
854567.0,Marinus Pharma Announces Offering of Common Shares,2015-11-05 17:07:00-05:00,MRNS,positive
854568.0,Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation,2015-10-29 07:49:00-04:00,MRNS,neutral
854569.0,Marinus Pharmaceuticals Reports Q3 EPS $(0.35) vs. Est. $(0.51),2015-10-29 07:47:00-04:00,MRNS,neutral
854570.0,Marinus Pharma Reports Key Initia Observations from Study in PCDH19 Female Pediatric Epilepsy: 63% of Patients Have Experienced Greater Than 50% Reduction for At Least One 28-Day Treatment,2015-10-26 07:32:00-04:00,MRNS,positive
854571.0,Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures,2015-09-09 07:31:00-04:00,MRNS,positive
854572.0,Marinus Pharmaceuticals Reports Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures,2015-09-09 07:31:00-04:00,MRNS,positive
854573.0,Published Data Backs Scientific Basis for Ganaxolone Use in PCDH19 Female Epilepsy,2015-07-06 07:30:00-04:00,MRNS,negative
854574.0,Marinus Pharmaceuticals Clinical Data of Ganaxolone in Pediatric Epilepsies at Antiepileptic Drug and Device Trials XIII Conference,2015-05-18 07:35:00-04:00,MRNS,neutral
854575.0,Morning Market Gainers,2015-03-25 09:37:00-04:00,MRNS,neutral
854576.0,Benzinga's Top #PreMarket Gainers,2015-03-25 08:15:00-04:00,MRNS,positive
854577.0,Marinus Pharmaceuticals' Ganaxolone Granted FDA Orphan Drug Designation in PCDH19 Female Epilepsy,2015-03-25 07:31:00-04:00,MRNS,positive
854578.0,FDA Grants Orphan Designation to Marinus Pharmaceuticals for Ganaxolone for Treatment of Protocadherin 19 (PCDH19) Female Epilepsy,2015-03-24 13:05:00-04:00,MRNS,positive
854579.0,Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy,2015-02-03 07:34:00-05:00,MRNS,neutral
854580.0,Marinus Pharmaceuticals Reports Q3 EPS of $(0.22) vs $(0.45) Est,2014-11-13 07:34:00-05:00,MRNS,neutral
854581.0,"Oppenheimer Initiates Coverage on Marinus Pharmaceuticals at Outperform, Announces $12.00 PT",2014-09-09 07:11:00-04:00,MRNS,neutral
854582.0,"JMP Securities Initiates Coverage on Marinus Pharmaceuticals at Market Outperform, Announces $14.00 PT",2014-08-26 08:33:00-04:00,MRNS,positive
854583.0,"Stifel Nicolaus Initiates Coverage on Marinus Pharmaceuticals at Buy, Announces $11.00 PT",2014-08-25 05:56:00-04:00,MRNS,neutral
854584.0,Marinus Pharma Announces Collaboration with Division of Ligand For Clinical Use of Captisol,2014-08-12 07:31:00-04:00,MRNS,neutral
854585.0,"Marinus Pharma Shares Open at $8/Share, IPO Priced at $8",2014-07-31 12:06:00-04:00,MRNS,positive
854586.0,Waiting on 11 IPOs This Morning,2014-07-31 09:34:00-04:00,MRNS,neutral
854587.0,IPO of 5.625M Shares by Marinus Pharma Priced at $8/Share,2014-07-31 09:28:00-04:00,MRNS,positive
854588.0,IPO Lookout: Busy Week Brings The Biggest IPO Since Facebook,2014-07-28 15:50:00-04:00,MRNS,neutral
854589.0,Marinus Pharmaceuticals Expects 4M Share IPO to Price $12.00-$14.00/Share,2014-07-18 08:08:00-04:00,MRNS,positive
